相似文献
1
How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?
Neurosci Bull. 2007 Nov;23(6):377-82. doi: 10.1007/s12264-007-0056-4.
2
Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons.
J Neurosci Methods. 2007 Oct 15;166(1):13-9. doi: 10.1016/j.jneumeth.2007.06.022. Epub 2007 Jul 1.
3
Transplantation therapy for Parkinson's disease.
Expert Opin Investig Drugs. 2000 Oct;9(10):2319-30. doi: 10.1517/13543784.9.10.2319.
4
Grafting of fetal dopamine neurons in Parkinson's disease. The Czech experience with severe akinetic patients.
Acta Neurochir Suppl (Wien). 1991;52:51-3. doi: 10.1007/978-3-7091-9160-6_15.
5
An in vitro interval before transplantation of mesencephalic reaggregates does not compromise survival or functionality.
Exp Neurol. 2004 May;187(1):58-64. doi: 10.1016/j.expneurol.2003.12.008.
6
Neural transplantation for the treatment of Parkinson's disease.
Lancet Neurol. 2003 Jul;2(7):437-45. doi: 10.1016/s1474-4422(03)00442-3.
7
Update on fetal transplantation: the Swedish experience.
Mov Disord. 1998;13 Suppl 1:83-7.
8
Microcarrier enhanced survival of human and rat fetal ventral mesencephalon cells implanted in the rat striatum.
Cell Transplant. 1997 Nov-Dec;6(6):579-84. doi: 10.1177/096368979700600608.
9
CNS immunological modulation of neural graft rejection and survival.
Neurol Res. 1996 Aug;18(4):297-304. doi: 10.1080/01616412.1996.11740425.
10
Graft outcomes influenced by co-expression of Pax7 in graft and host tissue.
J Anat. 2009 Mar;214(3):396-405. doi: 10.1111/j.1469-7580.2009.01049.x.
引用本文的文献
1
Stem-Cell-Based Therapy: The Celestial Weapon against Neurological Disorders.
Cells. 2022 Nov 2;11(21):3476. doi: 10.3390/cells11213476.
2
Stem Cell-Based Therapies for Parkinson Disease.
Int J Mol Sci. 2020 Oct 29;21(21):8060. doi: 10.3390/ijms21218060.
3
[Effect of the local application of stem cells on repairing facial nerve defects: a systematic review].
Hua Xi Kou Qiang Yi Xue Za Zhi. 2020 Feb 1;38(1):59-68. doi: 10.7518/hxkq.2020.01.011.
4
Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease.
EXCLI J. 2019 Mar 5;18:139-153. eCollection 2019.
5
In vitro maturation of dopaminergic neurons derived from mouse embryonic stem cells: implications for transplantation.
PLoS One. 2012;7(2):e31999. doi: 10.1371/journal.pone.0031999. Epub 2012 Feb 22.
6
Parkinson's disease in China.
Neurol Sci. 2011 Feb;32(1):23-30. doi: 10.1007/s10072-010-0461-8. Epub 2010 Dec 14.
本文引用的文献
1
Erythropoietin and Parkinson's disease: Suggested mechanisms and therapeutic implications.
Med Hypotheses. 2008;70(1):211-2. doi: 10.1016/j.mehy.2007.04.010. Epub 2007 Jun 5.
2
Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
Acta Med Okayama. 2007 Apr;61(2):51-6. doi: 10.18926/AMO/32888.
3
Intracerebral co-transplantation of liposomal tacrolimus improves xenograft survival and reduces graft rejection in the hemiparkinsonian rat.
Neuroscience. 2007 Apr 25;146(1):213-24. doi: 10.1016/j.neuroscience.2007.01.006. Epub 2007 Feb 14.
4
Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease.
PLoS One. 2007 Jan 24;2(1):e166. doi: 10.1371/journal.pone.0000166.
5
Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion.
J Neurosci. 2007 Jan 17;27(3):459-71. doi: 10.1523/JNEUROSCI.4493-06.2007.
6
Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.
Brain Res. 2007 Feb 23;1134(1):33-44. doi: 10.1016/j.brainres.2006.11.079. Epub 2006 Dec 28.
7
BDNF production by olfactory ensheathing cells contributes to axonal regeneration of cultured adult CNS neurons.
Neurochem Int. 2007 Feb;50(3):491-8. doi: 10.1016/j.neuint.2006.10.004. Epub 2006 Dec 8.
8
Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke?
Stroke. 2006 Oct;37(10):2453. doi: 10.1161/01.STR.0000239787.92203.16. Epub 2006 Aug 17.
9
Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease.
Eur J Neurosci. 2006 Jul;24(2):361-70. doi: 10.1111/j.1460-9568.2006.04919.x.
10
Transforming growth factor beta is required for differentiation of mouse mesencephalic progenitors into dopaminergic neurons in vitro and in vivo: ectopic induction in dorsal mesencephalon.
Stem Cells. 2006 Sep;24(9):2120-9. doi: 10.1634/stemcells.2005-0514. Epub 2006 Jun 1.
Zotero 插件